CL2016003283A1 - Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación - Google Patents

Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación

Info

Publication number
CL2016003283A1
CL2016003283A1 CL2016003283A CL2016003283A CL2016003283A1 CL 2016003283 A1 CL2016003283 A1 CL 2016003283A1 CL 2016003283 A CL2016003283 A CL 2016003283A CL 2016003283 A CL2016003283 A CL 2016003283A CL 2016003283 A1 CL2016003283 A1 CL 2016003283A1
Authority
CL
Chile
Prior art keywords
ezetimibe
rosuvastatin
oral administration
procedure
preparation
Prior art date
Application number
CL2016003283A
Other languages
English (en)
Inventor
Yong Ii Kim
Jae Hyun Park
Jong Soo Woo
Seung Jun Lee
Ha Young Jeong
Kyong Soo Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2016003283A1 publication Critical patent/CL2016003283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>SE PROPORCIONA UNA FORMULACIÓN COMPUESTA SÓLIDA PARA LA ADMINISTRACIÓN ORAL QUE INCLUYE; UNA PORCIÓN CORRESPONDIENTE A GRÁNULOS HÚMEDOS DE EZETIMIBA QUE INCLUYE EZETIMIBA QUE SE GRANULA POR VÍA HÚMEDA UTILIZANDO UN GRANULADOR DE LECHO FLUIDO; Y UNA PORCIÓN CORRESPONDIENTE A UNA MEZCLA DE ROSUVASTATINA QUE INCLUYE ROSUVASTATINA O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES.</p>
CL2016003283A 2014-06-25 2016-12-21 Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación CL2016003283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (ko) 2014-06-25 2014-06-25 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법

Publications (1)

Publication Number Publication Date
CL2016003283A1 true CL2016003283A1 (es) 2017-07-28

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003283A CL2016003283A1 (es) 2014-06-25 2016-12-21 Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación

Country Status (10)

Country Link
KR (1) KR101977785B1 (es)
AR (1) AR100977A1 (es)
BR (1) BR112016030111A2 (es)
CL (1) CL2016003283A1 (es)
EC (1) ECSP16096477A (es)
JO (1) JOP20150154B1 (es)
SG (2) SG10201811586YA (es)
TW (1) TWI700100B (es)
UY (1) UY36190A (es)
WO (1) WO2015199356A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016539A3 (cs) * 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
KR102206535B1 (ko) * 2016-11-29 2021-01-22 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
KR20200137243A (ko) 2019-05-29 2020-12-09 콜마파마(주) 로수바스타틴 및 에제티미브를 포함하는 복합제의 제조방법
BR112022001783A2 (pt) 2019-07-31 2022-03-22 Tecnimede Sociedade Tecnico Medicinal Sa Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
BR112023003323A2 (pt) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd Composição farmacêutica em forma de dosagem única
KR20250096941A (ko) 2023-12-20 2025-06-30 안국약품 주식회사 피타바스타틴 및 에제티미브를 포함하는 단일 정제 형태의 약학 조성물 및 이의 제조방법
KR20250161310A (ko) * 2024-05-08 2025-11-17 한미약품 주식회사 복약순응도가 개선된 에제티미브, 로수바스타틴 및 엠파글리플로진을 포함하는 복합제제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (ko) * 2007-09-05 2009-07-09 박재섭 이동부재를 이용한 골프 클럽
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
PT2459175T (pt) * 2009-07-28 2018-02-07 Egyt Gyogyszervegyeszeti Gyar Novo processo de granulação e o granulado assim preparado
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
ES2802252T3 (es) * 2012-05-01 2021-01-18 Althera Life Sciences Llc Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares

Also Published As

Publication number Publication date
KR20160000762A (ko) 2016-01-05
TWI700100B (zh) 2020-08-01
TW201625223A (zh) 2016-07-16
AR100977A1 (es) 2016-11-16
JOP20150154B1 (ar) 2021-08-17
WO2015199356A1 (en) 2015-12-30
UY36190A (es) 2015-10-30
ECSP16096477A (es) 2017-01-31
SG11201610748RA (en) 2017-01-27
BR112016030111A2 (pt) 2017-08-22
KR101977785B1 (ko) 2019-05-14
SG10201811586YA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CL2016003283A1 (es) Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
MX2016015636A (es) Formulaciones cannabinoides estables.
EP3622947B8 (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
DK4349406T3 (da) Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel
IL249061B (en) Combination, composition, and method of administering the combination or composition to animals
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
DK3674298T3 (da) Substituerede indazoler, fremgangsmåde til deres fremstilling, farmaceutiske præparater, der indeholder disse, samt deres anvendelse til fremstilling af lægemidler
PL3177329T3 (pl) Układ do natychmiastowego uwalniania substancji aktywnych
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2017000716A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
CL2014001828A1 (es) Sistema de dosificacion oral de liberacion dual que comprende doxilamina y piridoxina y/o sus analogos, metabolitos y sales de los mismos; forma de dosificacion oral de liberacion dual; kit farmaceutico; uso para aliviar los sintomas de nauseas y vomitos, incluidos los del embarazo.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
IL264880A (en) Preparations for oral administration of active substances
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
DK3258920T3 (da) Fast farmaceutisk doseringsform, der er egnet til anvendelse som drikkevandsmedikament
DOP2018000032A (es) Composición herbicida y proceso para prepararla
CL2018000306A1 (es) Agente para combatir los parásitos de peces
CL2017001466A1 (es) Un proceso para la fabricación de idalopirdina
MX374540B (es) Desmopresina estabilizada.
MA41216A (fr) Synthèse totale de trioxacarcine dc-45-a2 et préparation d&#39;analogues de trioxacarcine